Medicare drug plan seen as only short-term windfall for drugmakers

The new Medicare prescription drug plan would appear to be a windfall for the pharmaceutical industry, increasing earnings by 2% to 3% over the next two years; but in the long term the government and health plans are likely to negotiate lower prices, analysts and industry executives say.

View Full Article in:

San Jose Mercury News (Calif.) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC